Alan brings venture capital and pharmaceutical executive experience, having held leadership roles at Delin Ventures, AstraZeneca, and several therapeutics companies.
Novalis LifeSciences led the Series B round, which will fund team expansion and platform commercialisation.
"Our mission as a company is to enable widespread patient access to life saving cell and gene therapies. One of the biggest obstacles to achieving this is cell and gene therapy manufacturing processes that are too expensive, too highly variable and too low throughput. Our team is focused on the urgent need to enhance the ability of cell and gene therapy developers, CDMOs and Academic Medical Centers to deliver these therapies to as many patients as possible as quickly as possible,"
The seed follow on round was led by NFX with participation from existing investors.
"We see NFX's investment in Collective as a major vote of confidence in our ability to solve the protection gap problem for tens of millions of independent workers across the UK and Europe."
The Cambridge-based semiconductor IP supplier raised the funds to scale its engineering and commercial teams in Asia and North America.
"What excites us about Agile Analog is the potential for scale. Every other analog IP supplier is restricted to selling a limited range of standard IP products. But because Agile Analog’s unique technology enables it to create the IP that the customer wants, it can satisfy a wider range of customer requirements, and integrate more functionality into a chip design. As a result, the company is not limited by the size of today’s analog IP market – Agile Analog’s addressable market is potentially as big as the analog chip market. That is a huge opportunity which OMERS Ventures is pleased to help Agile Analog explore."
The seed follow-on round was backed by a consortium including AlbionVC, Delin Ventures, and Playfair Capital.
"Our technology can support healthcare providers in finding appropriate patients to participate in medical research including large scale patient registries which usually demands laborious, manual processes on top of their already complex and heavy workloads."
The Series A round was led by Northpond Ventures and Octopus Ventures to help bring the company manufacturing platform to market.
"Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs,"
The seed round was led by Stride.VC to support growth and product offerings for gig platforms.
"There are six million self-employed workers in the UK, which includes both higher-paid freelancers and gig economy platform workers. Yet, neither group typically has a safety net – no holiday pay, no family leave, no mental health support, not even paid sick days. We are building Collective Benefits so that the gig economy workers are covered by the same protections typically reserved for full-time employees."
The seed round was backed by Amadeus Capital Partners, Delin Ventures and Kindred Capital to fund the commercial launch of its manufacturing technology.
"Hundreds of clinical trials and a few recently marketed products have shown the revolutionary potential of CGTs. But this potential will never be realised unless we can remove the current bottleneck around scalable manufacturing. Ori Biotech has developed an innovative platform technology to facilitate scalable manufacturing that could eventually enable millions of patients to get access to the next generation of personalised medicines,"
Delin Ventures, firstminute Capital and MMC Ventures backed the round to support engineering expansion and product delivery.
"I’m delighted with the confidence that our investors have placed in us. This investment will enable us to deliver to our customers faster and make possible a paradigm shift in the $2Bn analog IP market."
